Cross-Border Merger
A merger combining two companies from different countries, subject to multiple regulatory, tax, and currency considerations.
What is Cross-Border Merger?
A cross-border merger is a combination of two companies domiciled in different countries into a single legal entity. Such transactions introduce layers of regulatory complexity not present in domestic deals: antitrust review may be required in multiple jurisdictions simultaneously, foreign investment screening mechanisms (such as CFIUS in the US or the UK National Security and Investment Act) can block or condition deals, and differing accounting standards (US GAAP vs. IFRS) complicate financial due diligence. Tax structuring is particularly sensitive, as the transaction may trigger exit taxes, transfer pricing scrutiny, and questions about the domicile of the surviving entity. Cultural integration, currency risk in deal pricing, and divergent labor laws add further execution challenges.
Example
In July 2021, AstraZeneca PLC (UK) completed its $39 billion acquisition of Alexion Pharmaceuticals Inc. (US), forming one of the largest cross-border pharmaceutical deals of that decade. The transaction required antitrust clearance from regulators in the United States, European Union, United Kingdom, Japan, Brazil, and several other jurisdictions. AstraZeneca gained Alexion's rare disease portfolio, including the blockbuster drug Soliris, while Alexion shareholders received a combination of cash and AstraZeneca ADRs.
Source: AstraZeneca Investor Relations